CSL has been one of the ASX’s huge success stories of the last decade but like most good growth stocks it got a bit ahead of itself from a valuation perspective hence MM wasn’t an owner for the majority of the last 2-years. However after its 30% correction we believe value has returned to this quality healthcare giant and we are now long in our Flagship Growth Portfolio, with a 6% weighting.
MM likes CSL under $270
Add To Hit List
